📷 Image: Wikimedia Commons / N. Vivekananthamoorthy
Business
Maharashtra FDA urges medtech price review, domestic manufacturers applaud
✍️ Business Standard
🗓 16 Sep 2026, 09:46 AM
👁 6
Domestic medical‑technology firms have welcomed the Maharashtra Food and Drug Authority’s call for a review of device prices, seeing it as a step toward more affordable healthcare.
The Maharashtra Food and Drug Authority (Maha FDA) has announced a comprehensive review of prices for medical devices sold in the state. The move aims to ensure that pricing is transparent and aligned with market realities, thereby improving access to essential health equipment.
Domestic manufacturers of medical technology have responded positively, stating that the review could help curb excessive pricing and make their products more competitive. Industry representatives said the initiative reflects the regulator’s commitment to balancing affordability with quality.
Analysts note that a price review could also encourage local firms to invest further in research and development, as a clearer pricing framework may reduce uncertainties in the market. The Maha FDA has not yet disclosed a timeline for the review, but it has indicated that stakeholder consultations will be part of the process.
The announcement comes amid broader efforts across India to control healthcare costs while promoting indigenous manufacturing under the "Make in India" agenda. If successful, the price review could set a precedent for other states to follow.
Domestic manufacturers of medical technology have responded positively, stating that the review could help curb excessive pricing and make their products more competitive. Industry representatives said the initiative reflects the regulator’s commitment to balancing affordability with quality.
Analysts note that a price review could also encourage local firms to invest further in research and development, as a clearer pricing framework may reduce uncertainties in the market. The Maha FDA has not yet disclosed a timeline for the review, but it has indicated that stakeholder consultations will be part of the process.
The announcement comes amid broader efforts across India to control healthcare costs while promoting indigenous manufacturing under the "Make in India" agenda. If successful, the price review could set a precedent for other states to follow.